Disease · MONDO_0006143

cervical squamous cell carcinoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. cervical squamous cell carcinoma. Diseases, record MONDO_0006143. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0006143

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: cervical squamous cell carcinoma; Open Targets
Open Targets ID: MONDO_0006143; Open Targets
Other names: cervical squamous cell cancer, cervix squamous cell carcinoma, cervix uteri squamous cell carcinoma, squamous cell carcinoma of cervix, squamous cell carcinoma of cervix uteri, squamous cell carcinoma of the cervix, squamous cell carcinoma of the cervix uteri, squamous cell carcinoma of the uterine cervix, squamous cell carcinoma of uterine cervix, squamous cervical cancer, uterine cervix squamous cell carcinoma; Open Targets
Disease Ontology: DOID:3744; Disease Ontology
NCI Thesaurus: C4028; NCI Thesaurus
Orphanet: ORPHA:213767; Orphanet
Highest stage of its drugs: Phase 3, for 5 of its 28 drugs, from ClinicalTrials.gov; Open Targets

Drugs28

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
CISPLATIN	CHEMBL11359	Small molecule	Phase 3	ClinicalTrials.gov	13	13	13	Drugs and targets
NIMOTUZUMAB	CHEMBL2108359	Antibody	Phase 3	ClinicalTrials.gov	6	6	6	Drugs and targets
PACLITAXEL	CHEMBL428647	Small molecule	Phase 3	ClinicalTrials.gov	6	6	5	Drugs and targets
CARBOPLATIN	CHEMBL1351	Small molecule	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
CEMIPLIMAB	CHEMBL4297723	Antibody	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
DOCETAXEL	CHEMBL3545252	Small molecule	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
CAMRELIZUMAB	CHEMBL4297715	Antibody	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
IPILIMUMAB	CHEMBL1789844	Antibody	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
NIVOLUMAB	CHEMBL2108738	Antibody	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
SERPLULIMAB	CHEMBL4594550	Antibody	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets

1 to 10 of 28

See all 28 drugs

Targets42

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
PDCD1	Programmed cell death protein 1	7	Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor	Phase 3	https://conductscience.org/library/genes/5133	Drugs and targets
CTLA4	Cytotoxic T-lymphocyte protein 4	3	Cytotoxic T-lymphocyte protein 4 inhibitor	Phase 2	https://conductscience.org/library/genes/1493	Drugs and targets
EGFR	Epidermal growth factor receptor	3	Epidermal growth factor receptor erbB1 inhibitor	Phase 3	https://conductscience.org/library/genes/1956	Drugs and targets
TUBA1A	Tubulin	3	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	3	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	3	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/84790	Drugs and targets
TUBA3C	Tubulin	3	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7278	Drugs and targets
TUBA3E	Tubulin	3	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/112714	Drugs and targets
TUBA4A	Tubulin	3	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7277	Drugs and targets
TUBB	Tubulin	3	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/203068	Drugs and targets

1 to 10 of 42

See all 42 targets

Trials36

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03257267	Study of Cemiplimab in Adults With Cervical Cancer	Phase 3	608	2022-04-06	Squamous Cell Carcinoma (SCC), Recurrent or Metastatic, Platinum-refractory Cervical Cancer	CEMIPLIMAB	Its record names the disease	ClinicalTrials.gov
NCT00025233	Bevacizumab in Treating Patients With Persistent or Recurrent Cancer of the Cervix	Phase 2	50	2015-06-29	Cervical Squamous Cell Carcinoma, Recurrent Cervical Cancer	BEVACIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT00193739	Neoadjuvant Chemotherapy Followed by Surgery Versus Concurrent Chemoradiation in Carcinoma of the Cervix	Phase 3	635		Cancer of Cervix	CARBOPLATIN, CISPLATIN, PACLITAXEL	Its record names the disease	ClinicalTrials.gov
NCT06333821	A Study of Nimotuzumab Plus Concurrent Chemoradiotherapy Sequential Maintenance Treatment for Cervical Carcinoma	Phase 3	460		Cervical Cancer	NIMOTUZUMAB	Its record names the disease	ClinicalTrials.gov
NCT04678791	Nimotuzumab Combined With Chemoradiotherapy Versus Chemoradiotherapy for Local Advanced Cervical Squamous Cell Carcinoma	Not applicable	286		Cervical Squamous Cell Carcinoma	CISPLATIN, NIMOTUZUMAB	Its record names the disease	ClinicalTrials.gov
NCT06419673	Serplulimab Plus Chemoradiotherapy for Stage III-IVA Cervical Cancer	Phase 2	240		Cervical Cancer	CARBOPLATIN, CISPLATIN, SERPLULIMAB	Its record names the disease	ClinicalTrials.gov
NCT06256224	Toripalimab Combined With Definitive CCRT for LACC Patients	Not applicable	150		Cervical Cancer, Chemoradiotherapy, Immunotherapy	TORIPALIMAB	Its record names the disease	ClinicalTrials.gov
NCT04976478	Study of Nimotuzumab Combined With IMRT in Elder Patients With Cervical Squamous Cell Carcinoma		125		Cervical Squamous Cell Carcinoma	NIMOTUZUMAB	Its record names the disease	ClinicalTrials.gov
NCT06781073	Nimotuzumab in Combined With Chemotherapy for Treatment of IVB Stage,Rrecurrent or Persistent Cervical Carcinoma	Phase 3	118		Cervical Squamous Cell Carcinoma, Persistent	CISPLATIN, NIMOTUZUMAB, PACLITAXEL	Its record names the disease	ClinicalTrials.gov
NCT04357873	Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations	Phase 2	112		Squamous Cell Lung Cancer, Vulvar Cancer, Penile Cancer, Cervix Cancer, Head and Neck Squamous Cell Carcinoma, Anal Cancer	PEMBROLIZUMAB, VORINOSTAT	Its record names the disease	ClinicalTrials.gov

1 to 10 of 36

See all 36 trials

Comparisons in its trials1

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial
Cemiplimab vs Investigator Choice (IC) Chemotherapy: Objective Response Rate (ORR) Assessed by Investigator Using RECIST 1.1	52 of 304	19 of 304	608	NCT03257267

Source Trial comparisons

Papers from its trials13

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
29432076	RESULT	1	PubMed
21840137	RESULT	1	PubMed
17049588	RESULT	1	PubMed
16478630	RESULT	1	PubMed
16271750	RESULT	1	PubMed
15310778	RESULT	1	PubMed
12821360	RESULT	1	PubMed
41958171	DERIVED	1	PubMed
41514314	DERIVED	1	PubMed
41468684	DERIVED	1	PubMed

1 to 10 of 13

See all 13 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0006143

GET https://conductscience.org/api/diseases/v1/MONDO_0006143/drugs?page=2

API reference For AI assistants